Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06801067 · ClinicalTrials.gov registry record · Phase 1
A Study of SER-155 to Treat Diarrhea in People on Immunotherapy
A Phase 1 study of Diarrhea and Enterocolitis, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 7
- Study locations
NCT06801067: Recruiting Phase 1 study of Diarrhea and Enterocolitis, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06801067 is a Phase 1 study of Diarrhea and Enterocolitis that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 15 participants, below the 156-participant average among 24 other Diarrhea trials with a reported enrollment target (90% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06801067, a Phase 1 study of Diarrhea and Enterocolitis, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to find out whether SER-155 may be a safe first treatment that causes few or mild side effects for people due to irEC.
Primary Outcome
Proportion of participants with treatment-related adverse events of special interest, i.e. blood stream infection
Conditions Studied
Interventions
- BIOLOGICAL SER-155
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited protocol activities) - Rockville Centre
New Jersey
- Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-01-24 |
| Est. Completion | 2027-01-24 |
| Phase | Phase 1 |
What NCT06801067 shows while recruiting
NCT06801067 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 156-participant average among 24 other Diarrhea trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Diarrhea appearing as the primary indexed condition, and to 1 intervention - of which SER-155 is the first listed.
NCT06801067 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT06801067 about?
NCT06801067 is a clinical study titled "A Study of SER-155 to Treat Diarrhea in People on Immunotherapy". The purpose of this study is to find out whether SER-155 may be a safe first treatment that causes few or mild side effects for people due to irEC.
What is the current status of trial NCT06801067?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2025-01-24. Estimated completion is 2027-01-24.
What conditions does trial NCT06801067 study?
This clinical trial studies the following conditions: Diarrhea, Enterocolitis.
What interventions are being tested in trial NCT06801067?
The interventions under investigation include: SER-155 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06801067?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06801067 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diarrhea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06801067's enrollment target sits among peer trials
15 24th of 24 higher than 1 of 24 other Diarrhea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diarrhea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
RECRUITING · Phase 1
-
First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults
RECRUITING · Phase 1
-
Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer
COMPLETED · Phase 1
-
Dose Escalating Study of Intramuscular Invaplex[AR-DETOX]
COMPLETED · Phase 1
-
Invaplex 50 Vaccine Dose-Ranging
COMPLETED · Phase 1
-
GI Alpha-Gal Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI